Jonathan MacQuitty

Jonathan currently serves as Industry Advisor with Catalys Pacific, Venture Partner with Lightspeed Venture Partners, and CEO of D2G Oncology, an oncology biotech start-up recently spun out of Stanford University.

Prior to his current positions, Jonathan served as CEO of Forty Seven, an immuno-oncology company that completed a $113 million IPO in 2018, from its inception until 2017. From 1999 to 2014, he was a Partner at Abingworth Management. Between 1988 until its acquisition 10 years later, he was founding CEO of GenPharm International. He began his career as a business development executive at Genencor and Genentech.

Other board directorships have included Acorda (now NASDAQ), Dicerna (now NASDAQ), Guava (acquired), Labcyte (acquired), Myelos (acquired), Orca, ParAllele BioScience (acquired), Personalis, Quantum Dot (acquired), SFJ Pharma, Sosei (listed in Tokyo), and Sunesis (listed on NASDAQ). He has also served on the Board of the Biotechnology Industry Organization (BIO).

Jonathan holds an M.A. in Chemistry from Oxford University, a Ph.D. in Chemistry from University of Sussex, and an M.B.A. from Stanford University.